Zeel
Zeel ®
Zeel® has been researched for over 40 years and has been used extensively by patients in approximately 20 countries. Each year, hundreds of thousands of patients are treated with Zeel® to treat degenerative joint disease. Zeel® is produced in Germany by Biologische Heilmittel Heel GmbH and distributed in 20 countries worldwide.
In Greece, Zeel® was granted a marketing authorization as an OTC medicine and is available in pharmacies from the company A.S.K. Pharmaceutical in two easy-to-use formulations: tablet and cream. Zeel® tablet1 is used to relieve the symptoms of pain and inflammation of the joint damage associated with arthropathy. Zeel® cream2 is used topically for the symptomatic treatment of arthropathy pain.
Characteristics
Arnica montana
Sanguinaria canadensis
Rhus toxicodendron
Each individually inhibit both LOX-5 and COX (COX-1 and COX-2)
Solanum dulcamara
Inhibits COX (COX-1 and COX-2), inhibits prostaglandin biosynthesis and PAF induced exocytosis.
Sanguinaria canadensis
Suppresses the proliferative effect of VEGF on endothelial cell line, probably mediated by blocking the VEGF-induced Akt activation.
Suitability
Adults and adolescents above 12 years old
No known drug interactions
Patients with hypersensitivity reactions against conventional treatment
Patients with contraindications to conventional treatment
Option for long term use
Health professionals
- Zeel Leaflet
- Citations
- Product Approved by EOF-Marketing Authorization Number 113721/17-11-2020
- Product Approved by EOF-Marketing Authorization Number 113722/17-11-2020
- Jäggi R, Würgler U, Grandjean F, Weiser M. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res. 2004;53(4):150-157.
- Tunon H, Olavsdotter C, Bohlin L. Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF induced exocytosis. J Ethnopharmacol. 1995;48:61-76.
- Basini G, Santini SE, Bussolati S, Grasselli F. Sanguinarine inhibits VEGFinduced Akt phosphorylation. Ann N Y Acad Sci. 2007;1095:371-376.
- Basini G, Bussolati S, Santini SE, Grasselli F. Sanguinarine inhibits VEGFinduced angiogenesis in a fibrin gel matrix. Biofactors. 2007;29(1):11- 18.
- Stančíková M, Bély M, Švík K, Metelmann HW, Schmolz MW, Ištok R, Fano R. Effects of Zeel comp. on experimental osteoarthritis in rabbit knee. Rheumatologia 1999;13(3): 101-108.
- Maronna U, Weiser M, Klein P. Orale Behandlung der Gonarthrose mit Zeel comp. Ergebnisse einer doppelblinden Äquivalenzstudie versus Diclofenac. Orthopädische Praxis. 2000;36(5):285-291.
- Strösser W, Weiser M. Patienten mit Gonarthrose gewinnen ihre Mobilität zurück. Biologische Medizin. 2000;29(6):295-9.
- Birnesser H, Klein P, Weiser, M. Treating Osteoarthritis of the Knee: A Modern Homeopathic Medication Works as well as COX 2 Inhibitors. Der Allgemeinarzt. 2003;25(4):261-264.
- Birnesser H. Stolt P, The homeopathic preparation Zeel comp. N: A review of the molecular and clinical data. Explore. (NY) 2007;3(1):16- 22.
Report side effects
- How can I report side effects?
Reporting of suspected adverse reactions.
Healthcare professionals are asked to report any suspected adverse reactions via the National Organization of Medicines. If you are a patient and you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the package leaflet. You can report adverse reactions with the following options:
1) Electronic submission through EOF’s website http://www.eof.gr/web/guest/yellowgeneral
2) Dispatching the Yellow card in hard copy via mail to EOF to the Department of Adverse Reactions (Mesogeion 284, Cholargos 15562)
3) Communication with the Department of Adverse Reactions via telephone: 213.20.40.380-337
4) Submission of the yellow card via fax at 210.6549.585
